Lightpoint Medical, a medical device company developing miniaturized surgical tools for advanced intraoperative cancer detection, received CE Mark approval for SENSEI, a robotic gamma probe to be commercially available to European hospital systems.
SENSEI has been designed for intraoperative detection of sentinel lymph nodes as well as cancer metastasis through the lymphatic system. The technology promises more precise, targeted cancer surgery and is applicable across a wide range of major cancer types, including lung, colorectal, stomach, gynecological, and prostate cancer.
Dr. David Tuch, CEO, Lightpoint Medical said: “Lightpoint is developing the most advanced intraoperative cancer detection technologies. Securing CE Mark for SENSEI is an important milestone in our efforts to transform cancer surgery and underscores our commitment to meet surgeons’ needs for miniaturized cancer detection tools as robotic platform technologies grow to dominate surgical practice. SENSEI promises accurate real-time cancer detection for robot-assisted cancer surgery. Currently, surgeons have no way to precisely detect cancer intraoperatively. As a result, millions of patients suffer every year as cancer is frequently left behind or healthy, functional tissue is needlessly removed.”
Dr. Jim Adshead, at the Lister Hospital, East and North Herts NHS Trust, UK said: “I am very excited about regulatory approval for SENSEI and now eager to start using it in surgery. I have been closely involved in the development of the technology since early usability testing, and I’m extremely hopeful for its potential in advancing the treatment of prostate cancer.”
Professor Declan Murphy, Robotic Surgeon, Peter MacCallum Cancer Center, Melbourne, Australia added: “I am delighted that SENSEI has received CE Mark. Our team is very keen to start using the technology in prostate cancer surgery using the da Vinci robot. As a leader in research in robot-assisted prostate cancer surgery and molecular imaging using PSMA, we are extremely excited about the prospects for SENSEI to improve outcomes for our patients.”
